Mangrove Partners Protagonist Therapeutics, Inc Transaction History
Mangrove Partners
- $642 Million
- Q4 2024
A detailed history of Mangrove Partners transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mangrove Partners holds 395,383 shares of PTGX stock, worth $15.3 Million. This represents 2.38% of its overall portfolio holdings.
Number of Shares
395,383
Previous 439,314
10.0%
Holding current value
$15.3 Million
Previous $19.7 Million
22.7%
% of portfolio
2.38%
Previous 2.57%
Shares
4 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
189KPut Options Held
191K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$229 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$163 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...